Purpose Direct-acting antiviral therapies (DAAs) for treatment of chronic hepatitis C virus
(HCV) have excellent rates of viral eradication, but their effect on regression of liver fibrosis …

Background There is a relationship between liver stiffness measurement (LSM) and
outcome of HCV patients. Aim To evaluate the performance of LSM to predict outcome of …

Ruling out advanced fibrosis/cirrhosis is mandatory for persons with hemophilia (PWH) who
are candidates for gene therapy. However, clinical evaluation and noninvasive tests (NITs) …

Abstract Background and Aim Virological cure becomes available for most patients with
chronic hepatitis C (CHC), but residual fibrosis can be an independent risk factor for liver …

Hepatocellular carcinoma (HCC) and variceal bleeding are among the most common
causes of liver-related mortality in patients with hepatitis C virus (HCV)-induced cirrhosis …

ABSTRACT BACKGROUND AND AIMS: Patients with HCV and advanced fibrosis remain at
risk of hepatocellular carcinoma (HCC) after sustained viral response (SVR) and need life …

Methods We applied multiparametric MRI to assess changes in liver composition, perfusion
and blood flow in 17 patients before direct-acting antiviral (DAA) therapy and after treatment …

Статья посвящена вопросам диагностики фиброза печени с использованием
неинвазивных методов оценки фиброза печени. Подробно рассмотрены методы …

Almost all patients achieved sustained virological response (SVR) by direct‐acting antivirals
(DAA) therapy, but it is not clear as to what extent DAA therapy affects changes in liver …

Background and Objectives: Direct-acting antivirals (DAAs) are highly effective for the
treatment of chronic hepatitis C virus (HCV) infection, but the risk of liver-related events and …